Associated tags: University, VIB, Biology, RNA, Rutgers University, Cell biology, Yale University, Pharmaceutical industry, Sarcoidosis, MOC, Patient, Idiopathic pulmonary fibrosis, International Institute for Nanotechnology, Laboratory, Cancer, Degenerative disease, Warsaw Stock Exchange, ARG2, Flemish Institute for Technological Research, ARG1
Locations: EU, WARSAW, PL, DENMARK, GREECE, POLAND, FRANCE, US, NORWAY, EUROPE, UK, GERMANY, LONDON, UNITED KINGDOM, EUROPEAN UNION, UNITED STATES
Medical device,
Annual report,
ARG1,
Documentation,
Biotechnology,
Sarcoidosis,
Partnership,
Patient,
Scientific Research Publishing,
USP7,
Ethics,
SPO,
Biomarker,
Research,
Health care,
Conception,
Cancer,
Messenger,
POC,
PLN,
Biology,
Royal,
MHRA,
Polish,
Clinical trial,
Safety,
MOC,
Phase,
ARG2,
Food,
FDA,
SMART,
CDA,
Pharmaceutical industry We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
Key Points:
- We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
- In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
- We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
- The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.
PET/CT,
Contract research organization,
Biotechnology,
Sarcoidosis,
Disease,
Patient safety,
Patient,
Tablet,
Spirometry,
Messenger,
Quality of life,
Biology,
Royal,
Fibrosis,
Clinical trial,
European,
Arrest,
Safety,
Pharmacokinetics,
MOC,
Phase,
KITE,
FDA,
FVC,
ECG,
Granuloma,
Pharmaceutical industry The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.
Key Points:
- The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.
- As part of the trial, patients will take a daily fixed dose of 25 mg OATD-01 or placebo tablets for 12 weeks.
- Patient safety will be monitored regularly through laboratory tests, neurological examinations and ECG and spirometry.
- The study will involve approximately 20-30 centres in the US, the European Union, Norway and the UK.
Retrieved on:
Monday, November 14, 2022
Idiopathic pulmonary fibrosis,
Yale University,
RNA,
International Institute for Nanotechnology,
VIB,
Sarcoidosis,
Biology,
University,
Cancer,
Degenerative disease,
Rutgers University,
Patient,
Warsaw Stock Exchange,
MOC,
Cell biology,
ARG2,
Flemish Institute for Technological Research,
ARG1,
Laboratory,
Pharmaceutical industry Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
Key Points:
- Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
- A Phase II trial in patients with sarcoidosis is expected to start in 2023.
- Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase I clinical development in the second half of 2022.
- Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in d. The company is listed on the Warsaw Stock Exchange (ticker: MOC).
Retrieved on:
Monday, November 14, 2022
Idiopathic pulmonary fibrosis,
Yale University,
RNA,
International Institute for Nanotechnology,
VIB,
Sarcoidosis,
Biology,
University,
Cancer,
Degenerative disease,
Rutgers University,
Patient,
Warsaw Stock Exchange,
MOC,
Cell biology,
ARG2,
Flemish Institute for Technological Research,
ARG1,
Laboratory,
Pharmaceutical industry Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
Key Points:
- Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready.
- A Phase II trial in patients with sarcoidosis is expected to start in 2023.
- Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase I clinical development in the second half of 2022.
- Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in d. The company is listed on the Warsaw Stock Exchange (ticker: MOC).
